Abstract
No public abstract is available from the verified source records.
Sue S Yom
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
10.1016/s0140-6736(26)01655-7 · 2026
Lung cancer
10.1016/s0140-6736(21)00312-3 · 2021
Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB–IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial
10.1200/jco-24-01681 · 2025
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
10.1016/s1470-2045(22)00518-6 · 2022
Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study
2026
Perioperative durvalumab for resectable non-small cell lung cancer: updated outcomes from the phase III AEGEAN trial
10.1200/jco-25-02659 · 2026
Perioperative nivolumab in resectable lung cancer
10.1056/nejmoa2311926 · 2024
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial
10.1016/j.annonc.2025.11.017 · 2026
Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial
10.1001/jama.2023.24735 · 2024
Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non-small cell lung cancer (NSCLC): KEYNOTE-867
2022
Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
10.1186/s40425-019-0583-3 · 2019
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
10.1016/s0140-6736(23)01384-3 · 2023
No additional external references are available.